Mohamed-Eslam F Mohamed

This inventor holds 37 USPTO granted patents and 26 published patent applications, plus 6 CIPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Abbvie Inc.. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mohamed-Eslam F Mohamed. Retrieved from https://idiyas.com/inventor/mohamed-eslam-f-mohamed

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 37 (Patent Applications = 26)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 6.4

ph-index = 18

Forward Citations = 595(Granted Patents)

Company Filing History:

37 out of 827

Abbvie Inc.

patents

Years Active: 2018-2026

Loading Chart...

Areas of Expertise:

Drug Preparation

Solid State Forms

Crohn's Disease

Ulcerative Colitis

Pyrrolidine

Trifluoroethyl

Imidazo

Pyrazin

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12570664 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2026-03-10),

2. 12365689 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2025-07-22),

3. 12134621 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2024-11-05),

4. 12116373 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2024-10-15),

5. 12110297 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2024-10-08),

6. 12103933 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2024-10-01),

7. 12091415 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2024-09-17),

8. 12077545 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2024-09-03),

9. 11993606 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2024-05-28),

10. 11993605 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2024-05-28),

11. 11976077 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms therof (2024-05-07),

12. 11795175 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2023-10-24),

13. 11787815 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof (2023-10-17),

14. 11780848 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof (2023-10-10),

15. 11780847 - Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof (2023-10-10),

Title: Innovations and Contributions of Mohamed-Eslam F Mohamed in Pharmaceutical Chemistry

Introduction

Mohamed-Eslam F Mohamed, based in Gurnee, IL, is an accomplished inventor in the field of pharmaceutical chemistry. With a remarkable portfolio of 35 patents, he has demonstrated significant contributions towards the development and synthesis of novel chemical compounds that play a crucial role in medical treatments.

Latest Patents

Among his most notable innovations are his latest patents related to the processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide. This disclosure specifically outlines procedures for preparing solid state forms of this compound, which is potentially impactful for pharmaceutical compositions and methods of treatment, including the management of rheumatoid arthritis. Furthermore, these patents detail kits, methods of synthesis, and products-by-process, making significant strides in the pharmaceutical industry.

Career Highlights

Currently, Mohamed-Eslam contributes his expertise at AbbVie Inc., a global biopharmaceutical company renowned for its innovations in various therapeutic areas. His role within the company emphasizes the application of his research and development skills to advance medical treatments and enhance patient care.

Collaborations

Throughout his career, Mohamed-Eslam has worked alongside notable colleagues such as Ahmed A Othman and Ben Klünder. These collaborations enhance the research environment and foster innovative solutions in the pharmaceutical sector, leveraging diverse expertise to tackle complex challenges.

Conclusion

In conclusion, Mohamed-Eslam F Mohamed's extensive work and patent portfolio place him among the leading inventors in pharmaceutical chemistry. His innovations not only contribute to scientific advancement but also hold the potential to transform treatment methodologies for various diseases. As he continues to work at AbbVie Inc., the future promises further developments that will undoubtedly impact the pharmaceutical landscape positively.

Profile summary based on public USPTO records.